@article{TAU26603,
author = {Salim K. Cheriyan and Marilin Nicholson and Ahmet M. Aydin and Mounsif Azizi and Charles C. Peyton and Wade J. Sexton and Scott M. Gilbert},
title = {Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors},
journal = {Translational Andrology and Urology},
volume = {9},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {Early stage nonseminomatous germ cell tumor (NSGCT) remains a treatable disease, with stage I cancer specific survival exceeding 95%. Using a risk-adapted approach; active surveillance (AS), adjuvant chemotherapy, and retroperitoneal lymph node dissection (RPLND) all options for treatment; with surveillance being increasingly used. With persistently elevated markers (stage IS), chemotherapy remains the hallmark of treatment. Management of stage II NSGCT varies based on status of tumor markers. With negative markers, both induction chemotherapy and upfront RPLND remain options. Management of a residual mass },
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/26603}
}